Atopic Dermatitis
From the Journals
Atopic dermatitis subtype worsens into midlife, predicting poor health
“A more comprehensive understanding of disease activity across the life span is needed,” the investigators wrote.
From the Journals
Atopic dermatitis doubles risk of mental health issues in children
In this study, unlike some previous studies, children were evaluated longitudinally, rather than in a single point in time.
News from the FDA/CDC
Three JAK inhibitors get boxed warnings, modified indications
The FDA is limiting all approved uses of tofacitinib, baricitinib, and upadacitinib to patients who have not responded well to TNF blockers, to...
Latest News
No link between childhood vaccinations and allergies or asthma
A meta-analysis by Australian researchers found no link between childhood vaccinations and an increase in allergies and...
Latest News
‘Gold cards’ allow Texas docs to skip prior authorizations
Through this law, doctors in the state will spend less time getting approvals for treatments for their patients.
Conference Coverage
UV light linked to prevention of allergic disease in infants
Researchers found that UV light exposure surpasses vitamin D supplements as an allergy prevention strategy in infants’ developing immune systems...
Latest News
Sublingual immunotherapy: Where does it stand?
Because there are few published trials of food SLIT, confusion about which doses are optimal, how early to start, and how long the benefits last...
Latest News
Direct-care allergy clinic specializes in sublingual immunotherapy
Few allergists treat food allergy patients with the immune-modifying treatment, sublingual immunotherapy, which delivers allergens through liquid...
Latest News
There’s a much safer food allergy immunotherapy – why don’t more doctors offer it?
For protecting against accidental ingestions, SLIT "is pushing pretty close to what OIT is able to provide but seemingly with a superior ease of...
Conference Coverage
Expert shares practical considerations when prescribing dupilumab
Real-world data suggests that the effectiveness of dupilumab is similar to the efficacy seen in clinical trials.
Conference Coverage
1 in 15 patients who start dupilumab may develop conjunctivitis, large analysis finds
“Compared to AD patients who received treatment with other systemic agents, dupilumab treatment doubled the risk of conjunctivitis in clinical...